Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acorda Therapeutics

Shionogi-ViiV to file HIV drug dolutegravir for approval

GSK, Pfizer and Shionogi joint venture completes phase III trials programme

- PMLiVE

Treating the brain with software

Clinical trials of game-like software designed to re-programme the brain and tackle some of the most intractable symptoms of schizophrenia could usher in a new way to treat a range...

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Pfizer calls on pharmacists to promote medicine adherence

Unused medicines cost NHS England £300m per year

FDA launches safety probe into Boehringer’s Mirapex

Regulator concerned about potential heart risk link to Parkinson's disease drug

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links